Valine is one of the three branched-chain amino acids (BCAAs) and is unique among them in that it is exclusively glucogenic — it is converted to glucose through the pathways of gluconeogenesis and does not produce ketones. Like all BCAAs, valine is metabolised directly in the skeletal muscle (bypassing the liver), where it is oxidised for energy or used for protein synthesis. Beyond its role as a metabolic fuel and a protein building block, valine has specific neurological functions that are distinct from the other BCAAs — particularly its role in modulating the NMDA receptor and in competing with the aromatic amino acids (phenylalanine, tyrosine, and tryptophan) for transport across the blood-brain barrier. These neurological functions make valine one of the most important amino acids for the prevention and management of hepatic encephalopathy — a complication of liver cirrhosis in which the accumulation of ammonia and the disruption of amino acid metabolism in the brain produce cognitive impairment, asterixis (the flapping tremor of the hands), and in severe cases, coma.
Valine and the Blood-Brain Barrier Transport System
The aromatic amino acids (phenylalanine, tyrosine, tryptophan) and the BCAAs (leucine, isoleucine, valine) compete for the same L-type amino acid transporter (LAT1) at the blood-brain barrier — this transporter has equal affinity for all of these amino acids, so the relative concentrations of the aromatic amino acids and the BCAAs in the plasma determine the relative uptake of each into the brain. In liver cirrhosis, the liver is unable to metabolise the aromatic amino acids (which are normally metabolised by the liver and removed from the portal blood), so plasma aromatic amino acid concentrations rise. Simultaneously, the catabolism of the BCAAs is increased (due to the insulin resistance and the elevated glucagon that characterise liver cirrhosis), so plasma BCAA concentrations fall. The resulting increase in the aromatic amino acid to BCAA ratio in the plasma drives a disproportionate increase in the uptake of aromatic amino acids into the brain, where they are metabolised to false neurotransmitters (such as octopamine from tyramine) that interfere with normal neurotransmitter function and contribute to the cognitive impairment of hepatic encephalopathy.
Valine supplementation is one of the primary treatments for hepatic encephalopathy — the rationale is that increasing valine intake will increase plasma valine levels, reduce the aromatic amino acid to BCAA ratio, and restore normal amino acid transport into the brain. A double-blind RCT in 40 patients with liver cirrhosis and hepatic encephalopathy found that valine supplementation at 0.24g/kg daily (approximately 15-20g daily for a 70kg adult) significantly improved cognitive function (measured by the trail-making test and the digit symbol substitution test) and reduced the severity of hepatic encephalopathy compared to placebo. This benefit was confirmed by a meta-analysis of 7 RCTs in patients with hepatic encephalopathy, which found that BCAA supplementation significantly improved cognitive function and reduced encephalopathy severity scores.
Valine and NMDA Receptor Modulation
Valine has also been studied for its potential effects on the NMDA receptor — the glutamate receptor that is the primary mediator of excitatory neurotransmission and synaptic plasticity in the brain. Like the other BCAAs, valine competes with glutamate for the NMDA receptor binding site (though with much lower affinity than glutamate), and high concentrations of valine can produce a mild competitive inhibition of the NMDA receptor. This NMDA receptor-modulating effect of valine may contribute to its anti-convulsant and anti-excitotoxicity effects, which have been documented in animal studies of valine supplementation. However, the clinical significance of this mechanism for human neurological conditions is not well-established.
Practical Application
For general valine supplementation, the evidence-based approach is to supplement with all three BCAAs rather than with valine alone — the standard BCAA supplement contains valine in proportions that reflect its dietary abundance (typically at a 2:1:1 ratio with leucine and isoleucine). The evidence-based dose for total BCAAs is 5-10g daily, split into 2-3 doses. For hepatic encephalopathy specifically, the evidence-based dose is 0.24g/kg daily of the BCAA mixture (or approximately 15-20g daily of BCAAs for a 70kg adult), which has been shown in clinical trials to significantly improve cognitive function and reduce encephalopathy severity. For comprehensive BCAA support, valine pairs well with the other BCAAs (leucine and isoleucine), with adequate protein intake (to provide the full complement of essential amino acids), with the vitamins and minerals that support BCAA metabolism (particularly vitamin B6 as PLP and magnesium, which are required for the transamination and decarboxylation reactions of BCAA metabolism), and with the hepatic encephalopathy management regimen (which includes lactulose, which reduces ammonia absorption from the gut).
Leave a Reply